From March 18-21, Apeloa Pharmaceuticals took part in DCAT Week in New York, an annual conference for key players in the bio/pharmaceutical space from around the world.

During the three-day conference, Apeloa shared with attendees its progress in increasing its R&D capacity and advanced manufacturing upgrades in recent years. In particular, the company highlighted its rich legacy in the CDMO business as well as its expansion plans in the future for technology platforms and advanced production capacity.

The yearly event was hosted by the Drug, Chemical and Associated Technologies (DCAT) Association, a non-profit Business Development Association of over 500 member companies. Among its invitees were representatives of global pharmaceutical companies and new drug R&D companies.

Apeloa was also widely recognized at DCAT Week by member companies for its exceptional service potential, R&D and production experience, customer reputation and management systems. It engaged in various face-to-face exchanges with new and old customers, speaking extensively about directions for their ongoing cooperation.

During the conference, Apeloa reiterated its focus on technological innovation and forging strategic partnerships, with the aim of improving high-quality productivity and core competitiveness.

Apeloa wishes to reaffirm and expand its role as a crucial part of the pharmaceutical industry chain. Its ultimate goal is to help global customers accelerate their R&D and listing of innovative drugs.

More about Apeloa Pharmaceuticals

Apeloa Pharmaceuticals, founded in 1989, is a healthcare company that manufactures and markets raw material medicines and preparations, including antitumour, antivirus, anti-infectious, cardiovascular and other medicines. It specialises in API, CDMO and Finished Dosage Form (FDF). The company is a subsidiary of Hengdian Group, and is listed on the main board of the Shenzhen Stock Exchange (SZSE: 000739).

More about DCAT week

DCAT Week is a yearly business development conference for companies in the field of pharmaceutical R&D, manufacturing and related industries. It provides a valuable opportunity for world-renowned pharmaceutical companies and professionals in these fields to meet and network.

DCAT is a non-profit global business development association with a unique membership model that integrates innovative and generic drug manufacturers, suppliers of raw materials, development and manufacturing services, as well as other professionals working in related industries.

Press Inquiries 

E-mail: press@hengdian.com